share_log

Lyell Immunopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-James Tananbaum (“Tananbaum”)(5.3%),Foresite Capital Fund IV, L.P. (“FCF IV”)(3.2%), etc.

SEC ·  Oct 31 17:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more